Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
Year: 2023
Type: conference-abstract
Source: Cancer Research
Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Institut Gustave Roussy, Weill Cornell Medicine, University of Milan, European Institute of Oncology, Harvard University, Dana-Farber Cancer Institute, Moffitt Cancer Center, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, German Breast Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365512580